Immunotherapy, a cutting-edge approach to treating diseases, particularly cancer, has revolutionized modern healthcare. This therapeutic strategy harnesses the body's immune system to combat diseases, offering a promising alternative to traditional treatments. This article provides a comprehensive insight into immunotherapy, its mechanism, applications, and challenges.
Immunotherapy works by stimulating or suppressing the immune system to help the body fight diseases. It can be classified into active, passive, and hybrid types, based on the approach used to manipulate the immune response. Active immunotherapy stimulates the immune system to respond to an antigen, while passive immunotherapy involves the administration of immune components, such as antibodies. Hybrid immunotherapy combines both strategies.
Immunotherapy has been primarily used for treating various types of cancer, including lung, skin, kidney, and lymphatic system cancers. It has also shown promising results in treating autoimmune diseases and allergies. The use of immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are some examples of immunotherapy in oncology.
Despite its significant potential, immunotherapy faces several challenges. These include the risk of severe immune-related adverse events, the high cost of treatment, and the lack of response in some patients. Additionally, identifying suitable biomarkers for predicting response to immunotherapy remains a major challenge.
With ongoing research and technological advancements, the scope of immunotherapy is expected to expand. Novel strategies, such as combination therapies and personalized immunotherapies, are being explored to overcome existing challenges and enhance efficacy.
In conclusion, immunotherapy signifies a paradigm shift in modern healthcare, offering a promising approach to treating a wide range of diseases. By understanding its mechanism, applications, and challenges, physicians can leverage this powerful tool to provide optimal patient care.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation